Cerenis Therapeutics SA, of Toulouse, France, said its Phase IIb CHI-SQUARE (Can HDL Infusions Significantly Quicken Atherosclerosis REgression?) study did not reach its primary endpoint in post-acute coronary syndrome (ACS) patients. The Phase IIb efficacy and safety trial randomized 507 patients with ACS at 53 centers in the U.S., Canada, France and the Netherlands.